Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 3Neuroendocrine Tumors 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1

Interventions

Irinotecan 7Cyclophosphamide 7Vincristine 6Magnetic Resonance Spectroscopy 5Dactinomycin 5temsirolimus 4cixutumumab 4X-Rays 4Sirolimus 4Radiotherapy 4Phantoms, Imaging 4Etoposide 4Doxorubicin 4Specimen Handling 3Radiation 3Peripheral Blood Stem Cell Transplantation 3Nuclear Medicine Department, Hospital 3Melphalan 3Ifosfamide 3Gemcitabine 3Filgrastim 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma × surufatinib × Clear all
NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡